CSL Ltd. — Capital/Financing Update 2022

Feb 13, 2022

For immediate release 14 February 2022

==> picture [205 x 32] intentionally omitted <==

==> picture [58 x 30] intentionally omitted <==

==> picture [262 x 27] intentionally omitted <==

CSL completes A$750 million Share Purchase Plan

CSL Limited (ASX:CSL; USOTC:CSLLY) (“CSL”) confirms the completion of its A$750 million (US$534 million)[1,2] Share Purchase Plan ("SPP") first announced on Tuesday, 14 December 2021.

The SPP complements two other capital management initiatives enacted in support of the proposed acquisition of Vifor Pharma Ltd (“Vifor Pharma”), including an Institutional Placement of A$6.3 billion (US$4.5 billion) (completed in December), and new long term debt facilities of US$6 billion, which will be finalised in due course.

In accordance with the SPP terms, the issue price of new shares under the SPP is A$253.57, which represents a 2.0% discount to the 5-day volume weighted average price of CSL shares up to and including the closing date of the SPP (Monday, 7 February 2022).

The SPP received strong support from eligible shareholders with a total of 56,180[3] individual holders participating. Valid applications totalled A$942,675,000.

As the total value of applications received under the SPP exceeded the SPP target size of A$750 million, CSL has undertaken a pro rata scale-back of applications consistent with the scale-back principles set out in the SPP booklet. These principles were structured with shareholder fairness in mind and designed to deliver as close to pro-rata outcome as possible.

The outcome is as follows:

• Eligible shareholders who applied for A$2,500 of shares will not be subject to any scale-back and will receive the amount they applied for, rounded down to reflect a whole number of shares. Accordingly, those shareholders will receive 9 new shares (for a total issue price A$2,282.13), with their remaining application monies to be refunded.

• Eligible shareholders who applied for more than A$2,500 of shares have been subject to the scale-back methodology having regard to their

1 Based on the USD:AUD exchange rate of 1.406 as of 13 December 2021. 2 Actual amount of proceeds from the Offer was A$750,028,363.75.

3 Including 17,828 custodian accounts.

==> picture [99 x 7] intentionally omitted <==

==> picture [58 x 30] intentionally omitted <==

==> picture [262 x 27] intentionally omitted <==

Page 2

shareholding as at the record date for the SPP[4] . The scale-back methodology ensures that, subject to the A$30,000 maximum application amount under the SPP, participating shareholders will receive an amount of new shares that:

• at least maintains their percentage shareholding in CSL held prior to the announcement of the Placement and SPP (“Pro Rata Amount”), subject to a minimum allocation of 9 new shares; or

• is equivalent to their application if that is lower than their Pro Rata Amount.

Approximately 94% of valid SPP applicants will receive at least their Pro Rata Amount[56] .

As a result, 2,957,875 new fully paid ordinary shares in CSL will be issued under the SPP today, Monday, 14 February 2022, with holding statements and refund monies being dispatched by Thursday, 17 February 2022. The shares issued under the SPP are expected to commence trading on the ASX on Tuesday, 15 February 2022 and will rank equally with existing CSL ordinary shares.

Shareholders can contact the SPP offer information line to obtain details of the number of shares they will receive under the SPP.

CSL’s Chief Executive Officer and Managing Director, Mr Paul Perreault said “We are delighted with the strong support we have received for the acquisition of Vifor Pharma from our shareholders. On behalf of the Board, I wish to thank all shareholders who participated in the SPP. We look forward to delivering on the exciting growth opportunities underpinning the acquisition of Vifor Pharma.”

Authorised by Fiona Mead

Company Secretary

4 The record date for the SPP is 7.00pm (AEDT) on Monday, 13 December 2021.

5 Provided they applied for at least their Pro Rata Amount. The pro rata shareholding of applicants was based on shareholdings as at the SPP record date, being 7.00pm (AEDT) on Monday, 13 December 2021.

6 A small number of shareholders with larger holdings (representing less than 6% of valid applicants) may have received less than their Pro Rata Amount as a result of the A$30,000 regulatory cap on applications.

==> picture [99 x 7] intentionally omitted <==

==> picture [58 x 30] intentionally omitted <==

==> picture [262 x 27] intentionally omitted <==

Page 3

FURTHER INFORMATION

For further information, please contact:

Shareholders:

CSL's SPP offer information line on 1800 646 882 (toll free within Australia) or +61 3 9415 4178 (from outside Australia) from 8:30am to 5:30pm (AEDT), Monday to Friday.

A copy of the share purchase plan offer booklet available for download at www.cslspp.com.au

Investors:

Media:

Mark Dehring Jimmy Baker Head of Investor Relations Communications CSL Limited CSL Limited Telephone: +613 9389 3407 Mobile +61 450 909 211 Email: mark.dehring@csl.com.au Email: jimmy.baker@csl.com.au

® Trademarks of CSL Limited or its affiliates.

==> picture [99 x 7] intentionally omitted <==